Does a pathogenic heterozygous ATM mutation alone warrant prophylactic bilateral salpingo‑oophorectomy?

Does ATM Mutation Warrant Prophylactic Bilateral Salpingo-Oophorectomy?

No, a pathogenic heterozygous ATM mutation alone does not warrant prophylactic bilateral salpingo-oophorectomy (BSO). Female ATM heterozygotes do not usually meet the risk threshold to consider risk-reducing salpingo-oophorectomy (RRSO), and it is generally not recommended 1.

Risk Assessment

The ovarian cancer risk in ATM heterozygotes is modestly elevated at approximately 2-3 times the general population risk 2. This translates to an absolute lifetime risk that falls well below the established thresholds (>10% lifetime risk) that typically warrant consideration of prophylactic surgery 3. For context:

• High-risk genes (BRCA1: 44%, BRCA2: 17%) clearly meet surgical thresholds
• Moderate-risk genes (RAD51C: 11%, RAD51D: 13%, BRIP1: 5.8%) may warrant RRSO
• ATM heterozygotes fall below these established risk levels

The 2025 ACMG guidelines explicitly state that the data on ovarian cancer does not support routine RRSO for ATM carriers 1.

When to Consider RRSO in ATM Carriers

RRSO may be discussed through shared decision-making in specific circumstances 1:

• Strong family history of ovarian cancer (multiple affected first- or second-degree relatives)
• Gynecological surgery already planned for other medical indications (e.g., fibroids, endometriosis)
• Age of cancer diagnosis in family members suggesting higher penetrance
• Other hormonal risk factors that compound baseline risk

Clinical Approach

For ATM heterozygotes without additional risk factors:

1. Do not routinely offer RRSO as the primary prevention strategy
2. Acknowledge the lack of effective ovarian cancer screening - there is no established early detection method 1
3. Focus surveillance efforts on breast cancer, where ATM confers more substantial risk (approximately 21% lifetime risk by age 80) 1
4. Document the discussion about the absence of proven ovarian cancer screening and the limited benefit of RRSO given the modest risk elevation

Important Caveats

The absence of routine RRSO recommendation does not mean zero risk. Patients should understand that while their ovarian cancer risk is elevated compared to the general population, it remains below the threshold where prophylactic surgery demonstrably improves mortality and quality of life outcomes. Unlike BRCA1/2 carriers, where RRSO reduces ovarian cancer risk by 80-96% and improves survival 3, the benefit-to-harm ratio for ATM carriers undergoing premature surgical menopause is unfavorable.

Avoid the pitfall of treating all hereditary cancer genes equivalently - ATM is a moderate-penetrance gene with different risk profiles for different cancers. The breast cancer risk warrants enhanced surveillance, but the ovarian cancer risk does not meet surgical intervention thresholds 1, 4.